Certain Names Clause Samples

The "Certain Names" clause defines how specific terms or names used throughout the contract are to be interpreted. It typically clarifies that references to individuals, companies, or entities in the agreement include their successors, assigns, or legal representatives, and may also address variations in spelling or formatting. This ensures that the contract remains clear and enforceable even if parties change names or if there are minor inconsistencies in how names are presented, thereby preventing disputes over identity or applicability.
Certain Names. All rights to use the corporate names, logos, trademarks or tradenames set forth in Section 2.02(b) of the Parent Disclosure Letter or any derivatives or variances thereof, including but not limited to the name "Hearst,", "The Hearst Corporation," or any derivatives or variances thereof;
View SourceView Similar (2)
Certain Names. All rights to use the corporate names, logos, trademarks or tradenames not set forth on ------------- Schedule 2.1(f) hereto or any derivatives or variances thereof which are not set forth on Schedule 2.1(f) hereto, --------------- --------------- including but not limited to, the name “Hearst”, “Hearst-Argyle”, the Hearst and Hearst-Argyle corporate logos and any derivatives or variances thereof;
View SourceView Similar (2)
Certain Names. All rights to use the name "Arms▇▇▇▇▇" ▇▇ substantially similar words, any corporate names, logos, trademarks or trade names containing or using "Arms▇▇▇▇▇" ▇▇ substantially similar words.
View Source
Certain Names. Notwithstanding anything herein to the contrary, no interest in or right to use the name "Schwarz" or any derivation thereof or any logo, trademark or trade nam▇ ▇▇ ▇▇ich Seller has any interest and which is not used in the Business (collectively, the "Retained Names and Marks") is being transferred to Buyer pursuant to the transactions contemplated hereby. Buyer agrees not to, and will cause its Affiliates not to, directly or indirectly use the Retained Names and Marks in the distribution, marketing or sale Nascobal units. Buyer acknowledges and agrees to re-label all Inventory purchased from Schwarz hereunder prior to the distribution, marketing or sale thereof ▇▇ ▇▇▇t such re-labeled Inventory contains no references to the Retained Names and Marks.
View Source
Certain Names. Except to the extent provided in the Holl▇▇▇▇▇ ▇▇▇ense Agreement, all rights to use the names "Holl▇▇▇▇▇," "Holl▇▇▇▇▇ ▇▇▇erchange," "Holl▇▇▇▇▇ ▇▇▇d Management System," "Smart Bid," "Accupart," "EDEN," "AutoInfo Interchange" and "ADP" or any derivatives or variances thereof;
View Source

Related to Certain Names

  • Business Names Other than its full corporate name, Borrower has not conducted business using any trade names or fictitious business names except as shown on the Supplement.

  • USE OF NAMES AND TRADEMARKS 16.1 Nothing contained in this AGREEMENT will be construed as conferring any right to use in advertising, publicity or other promotional activities any name, trademark, trade name, or other designation of either party hereto by the other (including any contraction, abbreviation, or simulation of any of the foregoing). Unless required by law or consented to in writing by REGENTS, the use by LICENSEE of the name "REGENTS of the University of California" or the name of any University of California campus in advertising, publicity or other promotional activities is expressly prohibited.

  • Domain Names Licensee represents that it does not own any Internet domain names containing Citi Marks.

  • Publicity; Use of Names Neither Party shall use the name, trademark, trade name or logo of the other Party, its Affiliates or their respective employee(s) in any publicity, promotion, news release or disclosure relating to this Agreement or its subject matter, without the prior express written permission of the other Party, except for those disclosures expressly authorized under this Article 4. Following execution of this Agreement, either Party may issue a press release announcing the existence of this Agreement in form and substance agreed to in writing by both Parties, such agreement to not be unreasonably withheld or delayed. Each Party agrees not to issue any other press release or other public statement disclosing other information relating to this Agreement or the transactions contemplated hereby without the prior written consent of the other Party, which consent shall not be unreasonably withheld or delayed; provided that Arvinas agrees that it shall be deemed reasonable for Pfizer to withhold its consent for the disclosure of any information related to a Target or a specific Compound or the amount of any payment made or to be made under this Agreement; and provided further that any disclosure which is required by Law or the rules of a securities exchange, as reasonably advised by the disclosing Party’s counsel, may be made subject to the following. Each Party agrees to provide to the other Party a copy of any public announcement regarding this Agreement or the subject matter thereof as soon as reasonably practicable under the circumstances prior to its scheduled release. Except under extraordinary circumstances or to the extent any such advance notice or notice period is not consistent with applicable Law, each Party shall provide the other with an advance copy of any such announcement at least [**] prior to its scheduled release. Each Party shall have the right to expeditiously review and recommend changes to any such announcement and, except as otherwise required by Law, the Party whose announcement has been reviewed shall remove any information the reviewing Party reasonably deems to be inappropriate for disclosure. The contents of any announcement or similar publicity which has been reviewed and approved by the reviewing Party can be re-released by either Party without a requirement for re-approval. In addition, except to the extent required by Laws in connection with patent enforcement activities conducted in accordance with Article 7, Pfizer shall not use the name “Yale” or “Yale University,” nor any variation or adaptation thereof, nor any trademark, trade name or other designation owned by Yale University, nor the names of any of its trustees, officers, faculty, students, employees or agents, for any purpose without the prior written consent of Yale University in each instance, such consent to be granted or withheld by Yale University in its sole discretion, except that Pfizer may state that it has sublicensed from Yale University one or more of the patents or applications comprising the Yale Licensed Patents.

  • Use of Names The Manager and the Fund agree that the Manager has a proprietary interest in the names “DFA” and “Dimensional,” and that the Fund and/or Portfolio may use such names only as permitted by the Manager, and the Fund further agrees to cease use of such names promptly after receipt of a written request to do so from the Manager.